Centrum 7/6  banner

infliximab

Pfizer biosimilar IXIFI approved by FDA

Pfizer biosimilar IXIFI approved by FDA

NEW YORK — Pfizer Inc. has received approval from the Food and Drug Administration for IXIFI (infliximab-qbtx), a biosimilar of Remicade (infliximab) from Janssen Biotech Inc. Pfizer said the FDA cleared IXIFI, a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, for the treatment of patients with rheumatoid arthritis, Crohn’s disease, pediatric Crohn’s disease, ulcerative

PP_1170x120_10-25-21